Treatment: Redefined Pharma Partnerships

April 1, 2015 By Benjamin Ryan

Pharmaceutical companies Janssen and Gilead Sciences have been working together to develop new single-tablet regimens (STRs) to treat HIV, and they recently changed the terms of their ongoing collaborations. Janssen has pledged to conduct all further development of the STR containing Janssen's Prezista (darunavir) and Gilead's Tybost (cobicistat), Emtriva (emtricitabine) and the not-yet-approved tenofovir alafenamide fumarate (TAF). [An updated version of tenofovir disoproxil fumarate (TDF), TAF leads to less bone and kidney toxicity.] Janssen will also be responsible for the manufacturing, registration, distribution and commercialization of the STR if it is approved. In addition, the two companies intend to swap TAF for TDF in Complera (emtricitabine/rilpivirine/TDF). Gilead will be in charge of the development and commercialization of the updated Complera in most countries, with Janssen heading up the commercialization in some others.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.poz.com/article/phamra-partnerships-27024-6483